Almotriptan (Almogran) is a 5-HT1B/1D receptor agonist (a triptan-class drug), widely used for the acute treatment of migraine in adults and adolescents aged 12 years and older. As a potent prescription medication, its clinical use must strictly comply with medication guidelines.

What Are the Side Effects of Almotriptan (Almogran)?

Common Side Effects

Digestive system: Nausea (2%), dry mouth (1%).

Nervous system: Paresthesia (e.g., tingling, burning sensation) (1%).

Adolescent patients (12-17 years old): Common reactions include dizziness (3-4%), drowsiness (5%), headache (1-2%), and vomiting (2%).

Severe Side Effects Requiring High Alert for Almotriptan (Almogran)

Cardiovascular System Risks

It may induce myocardial ischemia, myocardial infarction, or even life-threatening arrhythmias; some cases occur in patients without underlying heart disease.

If symptoms such as chest pain, a feeling of throat tightness, jaw pain, or difficulty breathing occur after medication administration, seek medical attention immediately.

Cerebrovascular Accidents

Rare but severe cerebral hemorrhage, subarachnoid hemorrhage, or stroke, which are particularly likely to be mistaken for migraine symptoms and lead to delayed treatment.

Peripheral vascular ischemic reactions: Such as Raynaud's syndrome, ischemic enteropathy (manifested as abdominal pain, bloody diarrhea).

Serotonin Syndrome

When used in combination with SSRI/SNRI antidepressants, life-threatening serotonin syndrome may occur.

Typical symptoms include: Mental abnormalities (agitation, hallucinations).

Autonomic disorders (tachycardia, blood pressure fluctuations).

Gastrointestinal symptoms: Nausea, vomiting, diarrhea.

Precautions for Almotriptan (Almogran) Use

Contraindication Screening

It is contraindicated in patients with ischemic heart disease, a history of cerebrovascular disease, or uncontrolled hypertension.

Dosage Adjustment for Special Populations

Patients with hepatic/renal impairment: The starting dose is 6.25 mg, and the maximum dose within 24 hours should not exceed 12.5 mg.

Medication Timing Control

It should only be used when a migraine attack is clearly confirmed; other triptan-class drugs or ergotamine-class drugs are prohibited within 24 hours.